Skip to main content
Psychedex
Article

Ethylone Facts

Stimulant; Entactogen; Substituted cathinone; Serotonin releasing agent

Description

Ethylone (3,4-methylenedioxy-N-ethylcathinone) — also known as bk-MDEA — is a synthetic stimulant-entactogen of the cathinone class. It blocks monoamine reuptake and actively releases serotonin, producing combined stimulant and emotionally opening effects.[1][2]

Subjective effects include euphoria, enhanced sociability, emotional warmth, heightened energy, sensory brightness, and wakefulness.[3] The experience sits between a clean stimulant push and a mild MDMA-like emotional openness — shorter and less emotionally deep, with a prominent energy edge.

No physical dependence data exist for ethylone, and no lethal dose or human overdose study has been published.[4][5] The primary dangers are cardiovascular stress and serotonin overload — both amplified by high doses or combination with other serotonin-raising drugs; the serotonin-dominant profile predicts lower compulsive redosing drive than more dopamine-focused cathinones.[6]

Dose and durationby route · individual sensitivity varies

Oral(mg)
Threshold< 75 mgLight75 – 125 mgCommon125 – 200 mgStrong200 – 325 mgHeavy325+ mg

Starts in 15 – 30 minLasts 2 – 4 hoursAfter-effects 2 – 8 hours

Body and dependence

Acute toxicity
Moderate
Chronic toxicity
Moderate
Physical dependence
Low
Psychological dependence
Moderate
Withdrawal
Mild
Compulsive redosing
Moderate

Tolerance

Builds
Moderate
Fully resets after
10 days
Carries over to
methylone; mephedrone; MDMA; amphetamine; cocaine

Effectslikely at a common dose

Perception
none likely · 7 possible, including Visual haze / noise
Body
Stimulation; Wakefulness; +25 possible, including Temperature dysregulation, Dehydration sensation, Excessive sweating
Thinking
none likely · 23 possible, including Compulsive redosing urge, Analysis suppression, Decision impairment
Feeling
Euphoria; +10 possible, including Depression, Anxiety, Anhedonia
Self
none likely · 8 possible, including Craving
Time
none likely · 2 possible
Awareness
none likely · 2 possible

Who shouldn't take it

Absolute
Cardiovascular disease; Epilepsy; Psychotic disorders; Pregnancy and breastfeeding; MAOI use; Concurrent serotonergic medication
Relative
Bipolar disorder

Combinations61 recorded

Lethal (2)
MAOIs; Tramadol
Dangerous (33)
Alpha-2 adrenergic receptor antagonist; Anticholinergics; Atypical antipsychotics; Caffeine; Dopamine agonists; Ephedrine, Pseudoephedrine; Local anesthetics; MDMA, Amphetamines; MDMA, MDA; NDRIs (Wellbutrin); NRIs; Opioids; SNRIs; SSRIs; Stimulants; 5-HTP, Tryptophan; Antihistamines; Antipsychotics; Buspirone; Clonidine, Guanfacine; DXM; GHB, Baclofen; GHB, GBL; Ibogaine; and 9 more, see full page
Caution (23)
See full page: psychedex.org/substances/ethylone
Not graded (3)
Not listed never means safe.

Seek help immediately if

  • Overheating / very high body temperature — heavy sweating, then hot dry skin (the leading cause of MDMA deaths, worse when dancing in hot venues)
  • Muscle rigidity, jaw clenching, tremor, or twitching (possible serotonin syndrome)
  • Fast, pounding heartbeat; chest pain
  • Agitation, confusion; seizures
  • Hyponatremia (water intoxication) — headache, confusion, drowsiness, vomiting, and seizures from drinking too much water
  • Nausea/vomiting; collapse or unconsciousness

What to do

  1. Move them somewhere cool and help them cool down — overheating is the main danger
  2. Sip water to stay hydrated but DO NOT overdrink — roughly a cup (250 ml) per hour if active; too much water can be deadly (hyponatremia)
  3. Get them to rest and stop dancing
  4. For overheating, seizures, chest pain, muscle rigidity/tremor, confusion, or unresponsiveness, call emergency services
  5. Recovery position if drowsy or vomiting; stay with them
  6. Be ready to give rescue breaths / CPR

Most resolve with cooling, rest, sensible hydration, and time. The life-threatening dangers are hyperthermia, serotonin syndrome, and hyponatremia (too much water) — each a medical emergency, not something to wait out.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1 · Not medical advice

References

  1. [1]
    ^Simmler LD, Buser TA, Donzelli M, et al. (2012) Pharmacological characterization of designer cathinones in vitro — British Journal of Pharmacology doi:10.1111/j.1476-5381.2012.02145.x
  2. [2]
    ^Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Swanson T, Johnson RA, Janowsky A (2017) Structure-Activity Relationships of Substituted Cathinones, with Transporter Binding, Uptake, and Release — Journal of Pharmacology and Experimental Therapeutics doi:10.1124/jpet.116.236349
  3. [3]
    ^Alcohol and Drug Foundation (Australia) (2023) Ethylone Drug Facts Link
  4. [4]
    ^Debruyne D, Loilier M, Cesbron A, Le Boisselier R, Bourgine J (2014) Emerging drugs of abuse: current perspectives on substituted cathinones — Substance Abuse and Rehabilitation doi:10.2147/sar.s37257
  5. [5]
    ^Luethi D, Liechti ME (2020) Designer drugs: mechanism of action and adverse effects — Archives of Toxicology doi:10.1007/s00204-020-02693-7
  6. [6]
    ^Gannon BM, Baumann MH, Walther D, Jimenez-Morigosa C, Sulima A, Rice KC, Collins GT (2018) The abuse-related effects of pyrrolidine-containing cathinones are related to their potency and selectivity to inhibit the dopamine transporter. — Neuropsychopharmacology doi:10.1038/s41386-018-0209-3
Print version
Report an issue